Scemblix
What Scemblix is used for
Scemblix is indicated for the treatment of adult patients with Philadelphia chromosome positive chronic myeloid leukaemia in chronic phase (Ph+ CML CP). Scemblix is indicated for the treatment of adult patients with Ph+ CML-CP with the T315I mutation who are resistant to, intolerant to or ineligible for ponatinib (see section 5.1).
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Scemblix
- Active substance
- asciminib
- Disease area
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Medicine group
- Antineoplastic agents
- ATC code
- L01EA06
- Marketing authorisation holder
- Novartis Europharm Limited
- Authorised in the EU since
- 2022
Official information
In the USA
Same active substance: Scemblix
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Scemblix used for?
Scemblix is indicated for the treatment of adult patients with Philadelphia chromosome positive chronic myeloid leukaemia in chronic phase (Ph+ CML CP). Scemblix is indicated for the treatment of adult patients with Ph+ CML-CP with the T315I mutation who are resistant to, intolerant to or ineligible for ponatinib (see section 5.1).
What is the active substance in Scemblix?
Scemblix contains asciminib.
Who makes Scemblix?
The EU marketing authorisation holder is Novartis Europharm Limited.
Is Scemblix an orphan medicine?
Yes. Scemblix is designated an orphan medicine in the EU, for a rare disease (Leukemia, Myelogenous, Chronic, BCR-ABL Positive).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU